DiaMedica Therapeutics (DMAC) Earnings Date, Estimates & Call Transcripts $3.51 -0.03 (-0.85%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$3.84 +0.33 (+9.40%) As of 08:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DiaMedica Therapeutics Earnings Summary Upcoming Earnings DateMay. 6After Market ClosesEstimatedConsensus EPS (Mar. 17) -$0.17 Actual EPS (Mar. 17) -$0.18 Missed By -$0.01 DiaMedica Therapeutics released Q4 2024 earnings on March 17, 2025, reporting an EPS of -$0.18, which missed analysts' consensus estimates of -$0.17 by $0.01. With a trailing EPS of -$0.60, DiaMedica Therapeutics' earnings are expected to decrease next year, from ($0.59) to ($0.80) per share. Q4 2024 Earnings ResourcesQ4 2024 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Annual Report (10-K)DMAC Upcoming EarningsDiaMedica Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Thursday, May 8, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Powered by Get DiaMedica Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DiaMedica Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataDMAC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Remove Ads DiaMedica Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.18-$0.18-$0.18Q2 20251-$0.18-$0.18-$0.18Q3 20251-$0.18-$0.18-$0.18Q4 20251-$0.18-$0.18-$0.18FY 20254($0.72)($0.72)($0.72) Remove Ads DiaMedica Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/6/2025(Estimated)--------3/17/2025Q4 2024-$0.17-$0.18 -$0.01-$0.18--8/7/2024Q2 2024-$0.16-$0.13+$0.03-$0.13--5/8/2024Q1 2024-$0.16-$0.14+$0.02-$0.14--3/20/2024--$0.14-$0.14--$0.14--11/13/2023Q3 2023-$0.14-$0.12+$0.02-$0.12--8/14/2023Q2 2023-$0.22-$0.16+$0.06-$0.16--5/15/2023Q1 2023-$0.16-$0.20 -$0.04-$0.20-- DiaMedica Therapeutics Earnings - Frequently Asked Questions When is DiaMedica Therapeutics's earnings date? DiaMedica Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based off last year's report dates. Learn more on DMAC's earnings history. Did DiaMedica Therapeutics beat their earnings estimates last quarter? In the previous quarter, DiaMedica Therapeutics (NASDAQ:DMAC) missed the analysts' consensus estimate of ($0.17) by $0.01 with a reported earnings per share (EPS) of ($0.18). Learn more on analysts' earnings estimate vs. DMAC's actual earnings. How can I listen to DiaMedica Therapeutics's earnings conference call? The conference call for DiaMedica Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read DiaMedica Therapeutics's conference call transcript? The conference call transcript for DiaMedica Therapeutics's latest earnings report can be read online. Read Transcript How much profit does DiaMedica Therapeutics generate each year? DiaMedica Therapeutics (NASDAQ:DMAC) has a recorded net income of -$19.38 million. DMAC has generated -$0.60 earnings per share over the last four quarters. What is DiaMedica Therapeutics's EPS forecast for next year? DiaMedica Therapeutics's earnings are expected to decrease from ($0.59) per share to ($0.80) per share in the next year. More Earnings Resources from MarketBeat Related Companies CureVac Earnings Date Xencor Earnings Date Prothena Earnings Date Replimune Group Earnings Date Arbutus Biopharma Earnings Date KalVista Pharmaceuticals Earnings Date ArriVent BioPharma Earnings Date Trevi Therapeutics Earnings Date Rocket Pharmaceuticals Earnings Date Pharming Group Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB? Remove Ads This page (NASDAQ:DMAC) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMusk's panic move: What the world's richest man fears is comingWhether you have modest savings of $10,000 or substantial wealth of $10 million, this information could determ...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DMAC Stock Free DMAC Stock Alerts